4DMedical Limited

OTCPK:FDMD.F Stock Report

Market Cap: US$128.5m

4DMedical Valuation

Is FDMD.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FDMD.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate FDMD.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate FDMD.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FDMD.F?

Key metric: As FDMD.F barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for FDMD.F. This is calculated by dividing FDMD.F's market cap by their current book value.
What is FDMD.F's PB Ratio?
PB Ratio2.8x
BookAU$70.93m
Market CapAU$199.11m

Price to Book Ratio vs Peers

How does FDMD.F's PB Ratio compare to its peers?

The above table shows the PB ratio for FDMD.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.1x
AMWL American Well
0.4x54.4%US$125.3m
SOPH SOPHiA GENETICS
1.9x19.0%US$234.5m
OPRX OptimizeRx
0.7x51.7%US$70.5m
TBRG TruBridge
1.3x116.1%US$226.5m
FDMD.F 4DMedical
2.8x46.0%US$199.1m

Price-To-Book vs Peers: FDMD.F is expensive based on its Price-To-Book Ratio (2.8x) compared to the peer average (1.1x).

Price to Book Ratio vs Industry

How does FDMD.F's PB Ratio compare vs other companies in the US Healthcare Services Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
UPHL UpHealth
0.0005xn/aUS$37.86k
PEAR.Q Pear Therapeutics
0.000005xn/aUS$142.00
No more companies available in this PB range
FDMD.F 2.8xIndustry Avg. 1.4xNo. of Companies6PB012345+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: FDMD.F is expensive based on its Price-To-Book Ratio (2.8x) compared to the US Healthcare Services industry average (1.5x).

Price to Book Ratio vs Fair Ratio

What is FDMD.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FDMD.F PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate FDMD.F's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst FDMD.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$0.62
0%
16.4%US$0.76US$0.52n/a3
Nov ’25US$0.34
US$0.62
+83.0%
16.4%US$0.76US$0.52n/a3
Oct ’25n/a
US$0.62
0%
16.4%US$0.76US$0.52n/a3
Sep ’25n/a
US$0.63
0%
20.7%US$0.81US$0.51n/a3
Aug ’25US$0.32
US$0.74
+129.8%
4.2%US$0.78US$0.71n/a3
Jul ’25n/a
US$0.74
0%
4.2%US$0.78US$0.71n/a3
Jun ’25US$0.41
US$0.74
+79.6%
4.2%US$0.78US$0.71n/a3
May ’25n/a
US$0.74
0%
4.2%US$0.78US$0.71n/a3
Apr ’25US$0.41
US$0.74
+81.8%
4.2%US$0.78US$0.71n/a3
Mar ’25US$0.47
US$0.74
+57.7%
4.2%US$0.78US$0.71n/a3
Feb ’25US$0.45
US$0.81
+80.1%
10.1%US$0.92US$0.72n/a3
Jan ’25n/a
US$0.85
0%
12.0%US$0.95US$0.74n/a2
Dec ’24US$0.60
US$0.78
+29.2%
19.1%US$0.93US$0.63n/a2
Nov ’24n/a
US$0.63
0%
12.8%US$0.71US$0.55US$0.342
Oct ’24n/a
US$0.63
0%
12.8%US$0.71US$0.55n/a2
Sep ’24n/a
US$0.63
0%
12.8%US$0.71US$0.55n/a2
Aug ’24US$0.53
US$0.72
+34.7%
4.5%US$0.75US$0.68US$0.322
Jul ’24n/a
US$0.72
0%
4.5%US$0.75US$0.68n/a2
Jun ’24n/a
US$0.72
0%
4.5%US$0.75US$0.68US$0.412
May ’24n/a
US$0.81
0%
14.3%US$0.93US$0.70n/a2
Mar ’24n/a
US$0.79
0%
18.6%US$0.94US$0.65US$0.472
Feb ’24n/a
US$0.91
0%
27.8%US$1.17US$0.66US$0.452
Jan ’24US$0.22
US$0.91
+311.9%
27.8%US$1.17US$0.66n/a2
Dec ’23n/a
US$0.91
0%
27.8%US$1.17US$0.66US$0.602
Nov ’23n/a
US$0.91
0%
27.8%US$1.17US$0.66n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Elevance Health

US$92.9b

Operates as a health benefits company in the United States.

ELV

US$400.70

7D

-5.8%

1Y

-13.9%

CVS Health

US$66.9b

Provides health solutions in the United States.

CVS

US$56.05

7D

0.4%

1Y

-17.9%

Patterson Companies

US$1.7b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

PDCO

US$20.90

7D

-0.7%

1Y

-34.7%